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Abstract. Target Nano-Pharmaceutics shall improve therapy and diagnosis of severe diseases, 
e.g. cancer, by individual targeting of drug-loaded nano-pharmaceuticals towards cancer cells, 
and drug uptake receptors in other diseases. Specific ligands, proteins or cofactors, which are 
recognized by the diseased cells or cells of food and drug uptake, are bound to the nanoparticle 
surface, and thus capable of directing the drug carriers. The strategy has two branches: a) for 
parenteral cancer medicine a ligand set (2-5 different, surface-linked) are selected according to 
the biopsy analysis of the patient tissue e.g. from tumor.; b) in the oral drug delivery part the 
drug transport is enforced by excipients/ detergents in combination with targeting materials for 
cellular receptors resulting in an induced drug uptake. Both targeting nanomaterials are 
characterized by a combination of SANS + DLS and SAXS or ASAXS in a feedback process 
during development by synthesis, nanoparticle assembly and formulation. 
1.  Synopsis and Concept 
Heavy metal loaded target Nanoparticles [1-3] shall improve therapy and diagnosis of severe diseases, 
e.g. cancer, by individual targeting [4,5] of drug-loaded nano-pharmaceuticals towards cancer cells. 
Specific protein or cofactor ligands, which are recognized by the diseased cells (cancer) or the drug 
uptake system, are bound to the nanoparticle surface, and thus capable of directing the drug carriers. In 
the concept a ligand set is coupled by a fast assembly technique (click link) in the very last step of the 
formulation. In the later clinical cancer therapy application the ligands set (2-5 different) will be 
selected according to the differential biopsy analysis of the patient tissue (tumor, healthy). The 
targeting nanomaterials are characterized and optimized by a combination of SANS+DLS [7] and 
SAXS, ASAXS, and radiotherapy tests with cells  in a feedback process during development. 
2.  Materials and Methods 
All materials were at least of analytical grade and obtained from Sigma-Aldrich Schnelldorf and Boeh-
ringer Ingelheim. The synthesis was done at the pharmaceutical institute of the Gutenberg University 
and Nanovel Ltd. & Co KG, Langenlonsheim (www.nanovel.de). The liposomes were prepared by the 
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film method with subsequent vortexing (1 min, 2400 rpm) yielding multilamellar vesicles MLV 
(160g/l), followed by addition of the drug stock solution and 11-fold extrusion through 100 nm 
polycarbonate membranes (Millipore). The DLS experiments were done as described earlier [7] at 633 
nm (5 mW HeNe laser, Uniphase) with a 5000/EPP correlator, SPIC-II single photon detector (ALV, 
Langen) and projecting DLS optics devive with 170° backscattering ProSpecD501 (Nanovel). The 
neutron scattering experiments were done at  the ILL at the D11 instrument, and the KWS-2 
instrument at the FRM-II reactor, MLZ Garching, with neutrons of 0.6 nm wavelength (9% Δ λ /λ). 
3.  Results and Discussion 
Fig.1: Target Nanoparticles can be applied by oral or parenteral ways. The ligands direct the drug 
carriers to specific cell receptors. The nanoparticle-ligand structure and dynamics, and the 
intermediate nano-assemblies with proteins and bile are studied by a combination of SANS and DLS.  
We synthesize and combine targeting excipients for oral drug delivery and modifiers of metal drug 
loaded nanoparticles for radiotherapy, which bear a specific receptor/carrier ligand domain at the end 
of a linker domain. The other end domain is hydrophobic, i.e. capable of drug binding (drug co-drug 
complex for oral application), or embedding into the surface of hydrophobic drug carrier nanoparticles 
for parenteral supply. In both cases the result is a drug carrier directed to specific receptor, as depicted 
in fig.1. All components are biocompatible and bio-degradable, which limits the selection of chemical 
structures, but prepares pharmaceutical licensing and medical application. The nanoparticles are 
biodegradable polymer [3], e.g. PLGA; ferrofluids [6], micelles [5,11,12], lipidic particles [7] or 
liposomes [8-10]. For oral application the ligand coupling is covalent, while the linkers for parenteral 
nano-pharmaceuticals are bound by cleavable S-S-bonds as terminal step of the preparation of a 
person- and case-specific medicine.  
The structure of the modified nanoparticles is analyzed by neutron small angle scattering SANS in 
combination with dynamic light scattering DLS [8,11,12], SAXS and metal specific X-ray scattering 
ASAXS, while the therapy effect of the drug is investigated with kinetic cell cultures as tumor models 
[1]. The attached protein shell resembles the protein corona formed by nanoparticles in the blood [13], 
but it consists of specific receptor targeting proteins, which are bound covalently. The particles in 
pharmaceutical samples depict a size scale of 1 nm to 100 µm in parallel. The nano-solutions are 
highly concentrated (up to 30 %, crowded conditions). Thus a combination of SANS, (A)SAXS and 
DLS is required [8], the latter as back scattering to avoid multiple scattering.  
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A) SANS : ILL-D11  
 
B) SAXS: ESRF-ID01 
   
Fig.2: Structure analysis of lanthanide entrapping liposomes (0.25M ErDTPA with (A) neutron small 
angle scattering and (B) synchrotron X-ray small angle scattering SAXS. 
Fig.2 depicts the structure analysis of liposome nanoparticles for radiotherapy with entrapped 
lanthanides [1-3] by SANS (ILL-D11) and SAXS (ESRF-ID01). The neutron small angle scattering 
gave radius of gyration (Rg = 21.3 ± 0.12 nm) and membrane span (4 nm) of the metal nanoparticles in 
highly concentrated D2O buffer (1.5 M ionic strength). The (A)SAXS investigation revealed a metal-
membrane interaction, which is indicated by the oscillation of the scattering curve in Fig.2B. The 
radiotherapy tests with cells as kinetic tumor model [1] depicted an increased photon induced cell 
inactivation, when the appropriate drug release was observed (t1/2 = 1 h @ c > 0.1 M entrapped drug). 
Acknowledgement: We thank for support by the German ministry of science and education BMBF, 
grant 05KS7UMA. 
References 
[1] Buch K, Peters T, Nawroth T, Sänger M, Schmidberger H, Langguth P 2012 Radiation 
Oncology 7, 1-6 
[2] Peters T, Grunewald C, Blaickner M, Ziegner M, Schütz C, Iffland D, Hampel G, Nawroth T, 
Langguth P 2015 Radiation Oncology 10, 52-64 
[3] “A particulate system for use in diminishing cell growth / inducing cell killing” 2012 EU-Patent 
11 007 401.0 ; PCT 13 07 12 keyword "Lanthanide", Johannes Gutenberg-Universität 
Mainz; inventors: Buch K, Nawroth T, Langguth P, Schmidberger H  
[4] Ferrara TA Hodge JW, Gulley JL 2009 Current Opinion in Molecular Therapeutics 11, 37-42  
[5] Alemdaroglu FE, Alemdaroglu NC, Langguth P, Herrmann A 2008 Adv. Materials 20, 899-902 
[6] Alexiou C, Schmid R, Jurgons R, Kremer M, Wanner G, Bergemann C, Huenges E, Nawroth T, 
Arnold W, Parak FG 2006 Eur Biophys J 35, 446-50 
[7] Johnson R., Nawroth T., Khoshakhlagh P., Langguth P., Szekely N.K., et al. 2014 Eur J Lipid 
Sci Techn 116, 1167-1173  
[8] Nawroth T., Buch P., Buch K., Langguth P., Schweins R  2011 Mol Pharmaceutics, 8, 2162-72  
[9] Nawroth T, Rusp M, May RP 2004 Physica B 350, e635-638  
[10] Hofmann AM, Wurm F, Hühn E, Nawroth T, Langguth P, Frey H. 2010 Biomacromolecules 11, 
568-574 
[11] Khoshakhlagh P, Johnson R, Nawroth T, Langguth P, Schmueser L, Hellmann N, Decker H, 
Szekely NK 2014 Eur J Lipid Sci Techn 116, 1155-116 
[12] Khoshakhlagh P, Johnson R, Langguth P, Nawroth T, Schmueser L, Hellmann N, Decker H, 
Szekely NK 2015 J Pharm Sci 104, 2213-24 
[13] Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, Knauer SK, Bantz C, Nawroth 
T, Bier C, Sirirattanapan J, Mann W, Treuel L, Zellner R, Maskos M, Schild H, Stauber RH 
2011 ACS Nano 5, 7155-7167 
VI European Conference on Neutron Scattering (ECNS2015) IOP Publishing
Journal of Physics: Conference Series 746 (2016) 012069 doi:10.1088/1742-6596/746/1/012069
3
